We aimed to investigate the effects of COVID-19 outbreak and public health measures on the psychological well-being of patients with psychiatric disorders. This cross-sectional study assessed 436 outpatients recruited from a tertiary psychiatry clinic in Istanbul, Turkey, nearly one month after the government introduced strict measures of lockdown against the ongoing outbreak. Respondents completed a web-based survey on sociodemographic data, subjective sleep quality, and a range of psychiatric symptoms using the Impact of Events Scale-Revised (IES-R), and Hospital Anxiety and Depression Scale (HADS). Respondents reported high frequencies of clinically significant posttraumatic stress disorder (PTSD) (32.6%, IES-R score ≥ 33), anxiety (36.4%, HADS anxiety score > 10), and depression (51%, HADS depression score > 10). 20.5% of respondents described that their psychological status worsened during the COVID-19 outbreak, and 12.1% of respondents described poor or very poor sleep in the prior month. Positive predictors of increased PTSD symptoms included the chronic medical diseases, knowing someone in the social vicinity diagnosed with the COVID-19 infection, job loss or being on temporary leave after the outbreak, and increased exposure time to TV or social media. In contrast, male gender, older age, higher educational attainment, and the psychiatric diagnoses of schizophrenia and (to a lesser degree) bipolar disorder were the negative predictors. Our results suggest that patients with psychiatric disorders are prone to substantial psychological distress during the COVID-19 outbreak, and various individual, behavioral, and social factors mediate this effect.
Introduction: The aim of this study was to investigate the clinical, radiological, and psychological correlates of mastalgia and to determine the factors independently associated with anxiety and depression in women presenting with breast pain. Methods: In this cross-sectional study, 151 women with mastalgia and 69 controls undergoing breast imaging were assessed. Sociodemographic variables, pain characteristics, clinical history, visual analog scale (VAS) scores, and Beck Anxiety Inventory (BAI) and Beck Depression Inventory (BDI) scores were collected. Radiological evaluation was performed using ultrasound or mammography based on age, and magnetic resonance imaging findings were included when available. Group comparisons were performed statistically using univariate tests and multivariate linear regression was used to identify predictors of anxiety and depression among patients with mastalgia. Results: Women with mastalgia demonstrated significantly higher anxiety scores than controls (median BAI 10 vs. 7; p = 0.009), whereas depression scores did not differ. Among patients with mastalgia, noncyclic pain, palpable abnormalities, and a history of breast surgery were associated with greater anxiety according to univariate analysis. In the multivariate model, palpable breast stiffness (β = 5.30; p = 0.013) and a history of previous breast surgery (β = 8.67; p = 0.022) independently predicted increased anxiety, whereas cyclic pain was protective (β = −6.40; p = 0.007). Imaging yielded predominantly benign or normal findings, underscoring the low diagnostic contribution of routine radiological workup. Conclusion: Mastalgia is characterized by a substantial psychological burden despite a low prevalence of radiological abnormalities. Clinical features, such as palpable stiffness and a history of prior breast surgery, are more strongly linked to anxiety than the findings from imaging studies. These results support a more selective imaging strategy and highlight the importance of incorporating psychological assessment in the evaluation of breast pain.
Background: In psychopharmacology, therapeutic window is the drug concentration range that ensures safe and effective outcomes, with a higher risk of treatment failure outside this range. Dopamine receptor partial agonists (DRPAs) illustrate this concept, particularly in treating depression, as they require specific doses to balance efficacy and safety. Methods: PubMed search focused on randomized controlled trials, open-label studies, and reviews evaluating aripiprazole, brexpiprazole, and cariprazine as augmentation therapies for major depressive disorder in adults. Results: Clinical trials on aripiprazole, brexpiprazole, and cariprazine as antidepressant adjuncts show that effective doses are typically lower than antipsychotic doses: 2-10 mg for aripiprazole (vs 10-30 mg), 2-3 mg for brexpiprazole (vs 4 mg), and 1.5-3 mg for cariprazine (vs 1.5-4.5 mg). At subantipsychotic doses, partial agonists increase dopamine signaling, while at antipsychotic doses they reduce it to the drug’s intrinsic activity level (generally 25%-40% of maximal dopamine signal) which is generally inadequate for an antidepressant response. Conclusion: DRPAs modulate the dopamine signaling depending on receptor occupancy: higher occupancy reduces signaling, while lower occupancy (when unoccupied receptors can interact with endogenous dopamine) enhances it. Understanding the drug-receptor relationship is crucial, since higher doses are not always more effective.
Lithium is the most reliable mood stabilizer available for the treatment of bipolar disorder. However, its use is limited by multiple concerns, including acute toxicity. Lithium levels have frequently been key to decisions regarding initiation of dialysis. Following the methodological principles of the Scale for the Assessment of Narrative Review Articles (SANRA), comprehensive searches were conducted across the following databases: PubMed, Embase, Web of Science, and Cochrane Library, without limitations on publication period. In an effort to standardize and objectify the decision to use dialysis, current treatment recommendations discuss clinical presentation but ultimately rely on measured serum lithium levels. Decision making can be improved if it takes into account whether lithium toxicity occurred slowly (which is equivalent to chronic toxicity, so that clinical signs of toxicity exceed expectations of measured lithium levels) or quickly (in which measured lithium levels exceed observed clinical severity). We propose that clinicians consider these factors and suggest that involving a broader interdisciplinary team, including psychiatry, in the decision-making process could enhance outcomes.